Literature DB >> 32243255

Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations.

Le Chang, Lei Zhao, Huafei Gong, Lunan Wang, Lan Wang.   

Abstract

Because of high rates of 2019 novel coronavirus disease in Wuhan, China, Wuhan Blood Center began screening for severe acute respiratory syndrome coronavirus 2 RNA on January 25, 2020. We screened donations in real-time and retrospectively and found plasma samples positive for viral RNA from 4 asymptomatic donors.

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; China; SARS; SARS-CoV-2; blood donors; coronavirus; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Substances:

Year:  2020        PMID: 32243255      PMCID: PMC7323524          DOI: 10.3201/eid2607.200839

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Because of the rapid increase of cases of 2019 novel coronavirus disease (COVID-19; 1) and detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in plasma (,), the safety of China’s blood supply became a major concern (). Most blood centers and blood banks in China began taking measures to ensure blood safety (); on January 25, 2020, we began screening all donations collected at the Wuhan Blood Center. We performed real-time reverse transcription PCR (RT-PCR) for SARS-CoV-2 RNA by using MultiScreen Pro RT-PCR assay (SYM-BIO LifeScience, https://www.sym-bio.com.cn). We performed pool testing by mixing plasma from 6–8 samples or individual testing by using 1.6 mL of plasma. We eluted 100 µL of nucleic acid template and added 40 µL of it to the RT-PCR mix. By March 4, we had screened 2,430 donations in real-time, including 1,656 platelet and 774 whole blood donations. We identified the first positive donor in our center in a positive pool with a weak amplification of the open reading frame 1ab gene. The donor gave 2 units of platelets on January 28, which were included in the pool. However, the donor’s prior donations collected on December 12 and 26 and January 13 were negative for viral RNA. Hubei Province Center for Disease Control and Prevention performed follow-up tests on plasma on February 2, which showed a weak positive result near the limit of detection; a throat swab specimen collected from the donor on February 10 also was positive, indicating an extremely low viral load in plasma. The donor reported no symptoms and was quarantined in a cabin hospital in Wuhan until 2 consecutive negative throat swab results on February 23 and February 25 (Figure).
Figure

Timeline of donations and symptom onset of 2019 novel coronavirus disease from 4 blood donors, China. Gray indicates a negative result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA; yellow indicates a positive result. Green indicates the donor was asymptomatic or their temperature returned to normal; orange indicates fever; red triangle indicates the donor’s fever subsided after taking self-prescribed antipyretic medications. PLT, platelet; TS, throat swab; WB, whole blood.

Timeline of donations and symptom onset of 2019 novel coronavirus disease from 4 blood donors, China. Gray indicates a negative result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA; yellow indicates a positive result. Green indicates the donor was asymptomatic or their temperature returned to normal; orange indicates fever; red triangle indicates the donor’s fever subsided after taking self-prescribed antipyretic medications. PLT, platelet; TS, throat swab; WB, whole blood. We also performed retrospective testing of 4,995 donations collected during December 21, 2019–January 22, 2020, by using retained nucleic acid template after routine pool testing. On February 10, we found a positive result in a nucleic acid template derived from donations collected on January 19. We individually tested samples that were in storage at 2°C–8°C for 23 days because no plasma samples stored at −20°C were available. We identified another positive donor of whole blood. We tested plasma products from his donation twice and noted similar results, which suggests that viral RNA is relatively stable in plasma (Appendix Table). We immediately traced all blood products produced from donor 2’s whole blood, and they had not been used. Telephone follow-ups on February 15 and 25 showed donor 2 remained asymptomatic and quarantined at home. In telephone follow-ups with donors who gave blood during January and February, we identified 33 donors who developed a fever after donation; all of their donations were removed from circulation. We performed retrospective individual screening on frozen plasma products from 17 donors and tested the retained nucleic acid templates after routine pool testing of the other 16 donors. We found 2 more positive donors who donated whole blood on January 20. Both had weak positive results, and donors reported fever onset on January 21 (Figure; Appendix Table). Donor 3 treated patients infected with SARS-CoV-2 in a Wuhan hospital. His temperature returned to normal 8 days after donation. Donor 4’s temperature also returned to normal 7 days after taking self-prescribed antipyretic medications. By March 4, we identified 4 blood donors in Wuhan whose plasma samples tested positive for SARS-CoV-2 RNA (Figure; Appendix Table). Samples from these donors were further tested for specific IgG and IgM against SARS-CoV-2 by ELISA; results were negative, indicating the possibility of infection in the early stage and the need to follow-up with these donors. We found SARS-CoV-2 RNA in plasma during routine screening of blood donors, considered a healthy population. We tested the 4 donors multiple times, using different sample sources, including sample tubes, retained nucleic acid templates, or blood products, indicating the accuracy and validity of our results (Appendix Table). One limitation of our study is that we did not have more detailed information on donors 2, 3, and 4. Although we could not confirm virions in blood or whether the virus could be transmitted in blood products, the potential risk should not be neglected. However, detectable RNA might not signify infectivity. Further studies, such as virus culture, should be done to explore the possibility of viremia and follow-up of donors also is essential. Of note, the donors all donated in late January, and we did not detect SARS-CoV-2 in plasma samples after then, indicating the strict containment measures taken by the government of China were effective. In China, donors are screened for related symptoms and asked if they feel healthy when they donate blood. Having donors call the blood donation center if they have any symptoms after donating is essential to avoid the risk of donation during the COVID-19 incubation period. Moreover, as more asymptomatic cases occur, screening donors for viral RNA with high-sensitivity assays, as we are doing in Hubei Province, will be critical to ensure blood safety. Appendix. Additional information on severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations.
  3 in total

1.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 2.  Coronavirus Disease 2019: Coronaviruses and Blood Safety.

Authors:  Le Chang; Ying Yan; Lunan Wang
Journal:  Transfus Med Rev       Date:  2020-02-21

3.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.

Authors:  Wei Zhang; Rong-Hui Du; Bei Li; Xiao-Shuang Zheng; Xing-Lou Yang; Ben Hu; Yan-Yi Wang; Geng-Fu Xiao; Bing Yan; Zheng-Li Shi; Peng Zhou
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

  3 in total
  83 in total

Review 1.  Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors:  Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  COVID-19 convalescent plasma therapy for immunodeficient patients-weighing up risks and benefits.

Authors:  T Vuk; A Hećimović; I Jukić; S Ravlić; T Kurtović; D Rnjak; B Halassy
Journal:  Transfus Clin Biol       Date:  2021-06-15       Impact factor: 1.406

3.  Coping with COVID-19 pandemic in blood transfusion services in West Africa: the need to restrategize.

Authors:  Henshaw Uchechi Okoroiwu; Ifeyinwa Maryann Okafor; Enosakhare Aiyudubie Asemota; Christopher Ogar Ogar; Ikenna Kingsley Uchendu
Journal:  Hematol Transfus Cell Ther       Date:  2021-03-01

4.  International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary.

Authors:  Arwa Z Al-Riyami; Thierry Burnouf; Mark Yazer; Darrell Triulzi; Levent Tufan Kumaş; Levent Sağdur; Nil Banu Pelit; Renée Bazin; Salwa I Hindawi; Maha A Badawi; Gopal K Patidar; Hem Chandra Pandey; Rahul Chaurasia; Roberta Maria Fachini; Patrícia Scuracchio; Silvano Wendel; Ai Leen Ang; Kiat Hoe Ong; Pampee Young; Jarkko Ihalainen; Antti Vierikko; Yan Qiu; Ru Yang; Hua Xu; Naomi Rahimi-Levene; Eilat Shinar; Marina Izak; Carlos Alberto Gonzalez; David Martin Ferrari; Paula Verónica Cini; Robby Nur Aditya; Ratti Ram Sharma; Suchet Sachdev; Rekha Hans; Divjot Singh Lamba; Lise Sofie H Nissen-Meyer; Dana V Devine; Cheuk Kwong Lee; Jennifer Nga-Sze Leung; Ivan Fan Ngai Hung; Pierre Tiberghien; Pierre Gallian; Pascal Morel; Khuloud Al Maamari; Zaid Al-Hinai; Hans Vrielink; Cynthia So-Osman; Vincenzo De Angelis; Pierluigi Berti; Angelo Ostuni; Giuseppe Marano; Michel Toungouz Nevessignsky; Magdy El Ekiaby; James Daly; Veronica Hoad; Sinyoung Kim; Karin van den Berg; Marion Vermeulen; Tanya Nadia Glatt; Richard Schäfer; Rita Reik; Richard Gammon; Melissa Lopez; Lise Estcourt; Sheila MacLennan; David Roberts; Vernon Louw; Nancy Dunbar
Journal:  Vox Sang       Date:  2021-05-20       Impact factor: 2.996

5.  Analysis of current SARS-CoV-2 infection in a large population of blood donors evidenced that RNAemia is rare in plasma.

Authors:  Daniel Gonçalves Chaves; Maria Clara Fernandes da Silva Malta; Luciana de Souza Madeira Ferreira Boy; Aretuza Miranda Barbosa; Cinthia Neves Fonseca; Dayanne Ellen de Lima Torres; Janaína Patterson Nogueira; Hélinse Medeiros Moreira; Flávia Cristine Martineli Loureiro; Jaciane Vargas de Freitas Silva; Maísa Aparecida Ribeiro; Júnia Guimarães Mourão Cioffi; Marina Lobato Martins
Journal:  Transfusion       Date:  2021-06-10       Impact factor: 3.337

6.  SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns.

Authors:  Arnaud G L'Huillier; Lara Danziger-Isakov; Abanti Chaudhuri; Michael Green; Marian G Michaels; Klara M Posfay-Barbe; Dimitri van der Linden; Anita Verma; Mignon McCulloch; Monica I Ardura
Journal:  Pediatr Transplant       Date:  2021-03-10

7.  Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.

Authors:  Fabrice Camou; Claire Tinevez; Mathilde Beguet-Yachine; Pantxika Bellecave; Diana Ratiarison; Camille Tumiotto; Xavier Lafarge; Olivier Guisset; Gaëlle Mourissoux; Marie-Edith Lafon; Fabrice Bonnet; Nahéma Issa
Journal:  J Med Virol       Date:  2021-05-03       Impact factor: 20.693

8.  Examination of the effects of COVID 19 on corneal endothelium.

Authors:  Seyfettin Erdem; Mine Karahan; Sedat Ava; Mehmet Emin Dursun; Leyla Hazar; Ugur Keklikci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-07       Impact factor: 3.117

9.  Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections.

Authors:  Enrico Richter; Doaa Al Arashi; Bianca Schulte; Christian Bode; Benjamin Marx; Souhaib Aldabbagh; Celina Schlüter; Beate Mareike Kümmerer; Johannes Oldenburg; Markus B Funk; Christian Putensen; Ricarda Maria Schmithausen; Gunther Hartmann; Anna Eis-Hübinger; Hendrik Streeck
Journal:  Transfus Med Hemother       Date:  2021-05-25       Impact factor: 3.747

10.  Transmission frequency of COVID-19 through pre-symptomatic and asymptomatic patients in AJK: a report of 201 cases.

Authors:  Majid Mahmood; Noor-Ul-Ain Ilyas; Muhammad Faraz Khan; Muhammad Naseem Hasrat; Nicholas Richwagen
Journal:  Virol J       Date:  2021-07-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.